Roche To Develop Gilead's Flu Drug

13 October 1996

- Gilead Sciences has struck a deal with Hoffmann-La Roche over its promising orally-active neuraminidase inhibitor for influenza, GS4104 (Marketletter September 30). Under the terms of the agreement, Roche gains worldwide rights to GS4104 and follow-ups, in return for a $10 million cash payment and up to $40 million in cash on the attainment of certain developmental and regulatory milestones. In addition, Roche will fund all R&D costs and pay Gilead royalties on sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight